Antiepileptics Library
ISO 17025–ACCREDITED LABORATORY ENVIRONMENT
Antiepileptic Drugs DMPK and Bioanalytical Services
Antiepileptic bioanalysis introduces a DDI dimension not seen in any preceding library page: CYP induction. Carbamazepine and phenytoin are CYP3A4 and CYP2C9/2C19 inducers — they upregulate enzyme expression, accelerating co-administered drug clearance toward sub-therapeutic exposure. This is the inverse of inhibition-based DDI. The remaining four antiepileptics span three additional identities: Phase I+II UGT+CYP (valproic acid), Phase II UGT only (lamotrigine), and non-metabolized excretion (levetiracetam, topiramate). A single incubation method applied across these six would need to cover CYP induction, UGT glucuronidation, and non-metabolic clearance simultaneously — three incompatible analytical worlds.
Creative Proteomics provides CYP induction-aware DDI profiling, UGT Phase II glucuronidation analysis, non-metabolized compound disposition, and custom multi-antiepileptic panels with mechanism-matched incubation arms.
CYP Induction: The Inverse of DDI InhibitionCarbamazepine and phenytoin upregulate CYP expression. Co-administered substrates are cleared faster — the opposite of inhibition-based DDI.
Phase II UGT GlucuronidationValproic acid (UGT+CYP) and lamotrigine (UGT1A4 only) require UDPGA. Lamotrigine needs no NADPH at all.
Non-Metabolized: Two RoutesLevetiracetam (minimal hydrolysis) and topiramate (renal excretion unchanged) bypass CYP and UGT entirely.
Antiepileptic Mechanism Risks DMPK Strategy Map
⚡
Mechanism ClassificationCYP inducer (carbamazepine, phenytoin), UGT+CYP (valproic acid), UGT only (lamotrigine), non-metabolized (levetiracetam, topiramate) — four analytical identities.
🧬
CYP Induction: Accelerated ClearanceCarbamazepine (CYP3A4) and phenytoin (CYP2C9/2C19) upregulate enzyme expression. Co-substrate clearance increases → sub-therapeutic exposure.
📊
UGT Phase II GlucuronidationLamotrigine (UGT1A4 only, UDPGA but no NADPH). Valproic acid (UGT+CYP2C9/2C19, both cofactors). Two Phase II strategies.
🔬
Non-Metabolized ClearanceLevetiracetam (minimal hydrolysis) and topiramate (renal excretion unchanged). No CYP or UGT incubation contributes meaningful data.
Antiepileptic mechanism audit before method development.Creative Proteomics classifies each compound as CYP inducer, CYP+UGT substrate, UGT-only substrate, or non-metabolized — because induction, glucuronidation, and non-metabolic clearance require three mutually incompatible incubation protocols.
